Adastra Holdings Ltd. (XTXXF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Adastra Holdings Ltd. (XTXXF) Healthcare & Pipeline Overview

Adastra Holdings Ltd. is a Canadian-based cannabis extraction and processing company, offering analytical testing and comprehensive processing solutions. It supplies concentrated cannabis derivatives to business-to-business clients domestically and internationally, positioning itself within the evolving global legal cannabis market.

What Is the Investment Thesis for XTXXF?

Adastra Holdings Ltd. operates with a business model centered on cannabis extraction, processing, and analytical testing, serving the expanding global legal cannabis market. Key value drivers include its specialized expertise in producing concentrated cannabis derivatives for business-to-business (B2B) clients, both domestically in Canada and internationally. The company's ability to provide comprehensive processing solutions to authorized growers positions it as a critical infrastructure provider within the cannabis supply chain. Growth catalysts are anticipated from the continued global legalization and destigmatization of cannabis, driving increased demand for high-quality derivatives. Further opportunities may arise from expanding its product portfolio of concentrates or entering new international markets. However, the investment thesis must acknowledge significant risks, notably the company's current unprofitability, evidenced by a -85.9% profit margin, and its small market capitalization of $0.00B. The gross margin of 32.3% indicates some operational efficiency at the production level, but overall expenses outweigh revenue. Furthermore, its listing on the OTC Other tier implies higher risk due to potentially limited liquidity and less stringent disclosure requirements. Investors should closely monitor the company's path to achieving positive net income and its ability to navigate the evolving regulatory landscape while scaling operations effectively.

Based on FMP financials and quantitative analysis

XTXXF Key Highlights

Market Capitalization of $0.00B, indicating a micro-cap or unvalued status within the public markets.

• Profit Margin of -85.9%, highlighting significant current unprofitability for the company.
• Gross Margin of 32.3%, demonstrating a degree of efficiency in its core extraction and processing operations before operating expenses.
• Beta of -0.47, suggesting an unusual inverse relationship with overall market movements.
• Specialization in cannabis extraction, processing, and analytical testing, serving B2B clients domestically and internationally.

Who Are XTXXF's Competitors?

XTXXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XTXXF's Key Strengths?

Specialized expertise in cannabis extraction and processing, offering comprehensive solutions.

• Established analytical testing capabilities for quality assurance and regulatory compliance.
• Existing B2B client base and international supply capabilities for concentrated derivatives.
• Long operational history since 1987 (as Phyto Extractions Inc.) providing industry experience.

What Are XTXXF's Weaknesses?

Significant unprofitability, evidenced by a -85.9% profit margin.

• Small market capitalization of $0.00B, potentially limiting access to capital.
• Limited employee base of 21, which may constrain scalability and operational breadth.
• OTC Other tier listing, implying higher risk and potentially limited liquidity.

What Could Drive XTXXF Stock Higher?

Expansion into new international legal cannabis markets, leveraging existing worldwide supply capabilities.

• Introduction of new cannabis derivative products or specialized formulations catering to evolving market demands.
• Achievement of sustained positive net income, moving away from the current unprofitability.
• Evolution and maturation of cannabis regulatory frameworks in key operational and target markets.
• Increased demand for high-quality cannabis derivatives driven by global legalization trends.

What Are the Key Risks for XTXXF?

Financial-distress signal — its Altman Z-Score of -5.87 sits in the distress zone (elevated bankruptcy risk).

• Significant unprofitability, as evidenced by a -85.9% profit margin, posing challenges to long-term sustainability.
• Evolving and complex regulatory landscape in the global cannabis industry, requiring continuous adaptation and compliance.
• Limited liquidity and higher trading risk associated with its OTC Other listing, impacting investor confidence and capital access.
• Intense competition from other cannabis processors and extractors, potentially leading to pricing pressures and market share erosion.
• Capital constraints impacting growth initiatives and operational scaling, given the current market cap and profitability challenges.

What Are the Growth Opportunities for XTXXF?

• The ongoing global trend towards cannabis legalization and decriminalization presents a substantial growth avenue. As more countries and regions establish regulated cannabis markets, the demand for high-quality, compliant cannabis derivatives is expected to surge. Adastra, with its existing international supply capabilities, is well-positioned to capitalize on these emerging markets.
• Beyond traditional THC and CBD concentrates, the cannabis industry is witnessing growing interest in minor cannabinoids such as CBG, CBN, and CBC, as well as custom formulations for specific applications. Adastra's extraction and processing expertise allows for the development and production of a broader range of specialized derivatives. This diversification can open new revenue streams by catering to B2B clients developing novel products for health, wellness, and recreational markets, potentially commanding higher margins for unique, high-purity extracts. The market for these specialized compounds is nascent but growing rapidly.
• As regulatory frameworks mature and consumer safety becomes a paramount concern, the demand for independent, accredited analytical testing for cannabis products is set to intensify. Adastra's existing analytical testing capabilities can be expanded to serve a wider array of third-party growers and processors. This segment offers a stable revenue stream, as testing is a mandatory requirement for product market entry in most legal jurisdictions, ensuring product potency, purity, and safety from contaminants. This market is driven by compliance and quality assurance needs.
• Given the fragmented nature of the cannabis industry, strategic collaborations or targeted acquisitions could significantly enhance Adastra's market footprint, operational capacity, and technological capabilities. Partnering with large-scale cultivators could secure raw material supply, while acquiring smaller, specialized processors could expand product offerings or geographic reach. Such inorganic growth strategies could accelerate market penetration and consolidate Adastra's position as a leading B2B supplier of cannabis derivatives, particularly in regions where it seeks to establish a stronger presence.
• Adastra currently supplies concentrated cannabis derivatives to qualified B2B clients worldwide. Further aggressive expansion into specific, high-growth international markets where cannabis legalization is progressing, such as parts of Europe or emerging Asian markets, represents a significant opportunity. This involves navigating diverse regulatory landscapes and establishing robust supply chains to meet local demands. By leveraging its existing global supply network and expertise in regulatory compliance, Adastra can strategically target and capture market share in these nascent but potentially lucrative international territories for cannabis derivatives.

What Are XTXXF's Competitive Advantages?

• Specialized expertise and established infrastructure in cannabis extraction and processing techniques.
• Proprietary knowledge and capabilities in analytical testing for cannabis products, ensuring quality and compliance.
• Existing network of qualified business-to-business (B2B) clients in both domestic and international markets.
• Experience in navigating the complex and evolving regulatory landscape of the global cannabis industry.

What Does XTXXF Do?

Adastra Holdings Ltd., headquartered in Langley, Canada, operates as a specialized entity within the cannabis industry, focusing primarily on extraction and processing. Established in 1987, the company initially operated under the name Phyto Extractions Inc. before undergoing a strategic rebranding to Adastra Holdings Ltd. in September 2021. This evolution reflects its adaptation and strategic positioning in the burgeoning legal cannabis and hemp markets, moving beyond its initial identity to encompass a broader scope of services. The firm provides a critical suite of services, including advanced analytical testing for cannabis products, which is essential for ensuring compliance with stringent regulatory standards and maintaining quality assurance across the supply chain. This testing capability is a cornerstone of its operations, offering reliability and validation for both its own products and those of its clients. Beyond analytical testing, Adastra offers comprehensive processing solutions, leveraging its deep expertise to support authorized cannabis and hemp growers throughout their production cycles. This support encompasses the intricate processes required to transform raw plant material into various concentrated cannabis derivatives. These derivatives, which can include a range of products such as oils, distillates, and isolates, are then meticulously prepared and supplied to a diverse clientele of qualified business-to-business (B2B) clients. The company's operational reach is not confined to its domestic Canadian market; it actively engages in supplying these concentrated derivatives to international B2B clients as well, underscoring its global aspirations within the specialty drug manufacturing sector. By focusing on the B2B segment, Adastra positions itself as a crucial intermediary, enabling other cannabis businesses to bring their products to market efficiently and in compliance with the complex requirements of the industry. Its specialization in extraction and processing, coupled with its robust analytical capabilities, allows it to cater to the increasing demand for high-quality, consistent cannabis concentrates that form the basis for a wide array of consumer and medical cannabis products.

What Products and Services Does XTXXF Offer?

• Specializes in cannabis extraction from raw plant material.
• Provides comprehensive cannabis processing solutions.
• Offers analytical testing services for cannabis products.
• Supports authorized cannabis and hemp growers with processing expertise.
• Supplies concentrated cannabis derivatives to business-to-business (B2B) clients.
• Operates and supplies products within Canada.
• Engages in supplying concentrated cannabis derivatives worldwide.

How Does XTXXF Make Money?

• Generates revenue from providing cannabis extraction and processing services to growers.
• Earns income from offering analytical testing services for cannabis products.
• Sells concentrated cannabis derivatives directly to qualified B2B clients.
• Leverages its processing expertise to support authorized cannabis and hemp growers' production needs.

What Industry Does XTXXF Operate In?

Adastra Holdings Ltd. operates within the dynamic and rapidly evolving global cannabis industry, specifically categorized under "Drug Manufacturers - Specialty & Generic" due to its focus on cannabis derivatives. The market is characterized by ongoing legalization efforts across various jurisdictions, leading to a significant increase in demand for processed cannabis products and concentrates. Adastra's position as a specialized extractor, processor, and analytical testing provider places it as a crucial B2B supplier within this ecosystem. The competitive landscape is fragmented, with numerous players ranging from large multi-state operators to smaller, specialized firms. Adastra differentiates itself through its comprehensive processing solutions and international supply capabilities for concentrated derivatives. Key market trends include the increasing consumer preference for diverse cannabis products beyond raw flower, such as oils, edibles, and vapes, all of which rely on high-quality extracts. Regulatory compliance and product consistency are paramount in this sector, areas where Adastra's analytical testing services provide a competitive edge.

Who Are XTXXF's Key Customers?

• Authorized cannabis growers requiring processing and extraction services.
• Authorized hemp growers seeking processing and extraction solutions.
• Qualified business-to-business (B2B) clients purchasing concentrated cannabis derivatives.
• Companies in need of third-party analytical testing for cannabis products.

Wall Street analysts project Adastra Holdings Ltd. revenue of about $4.8M for fiscal 2026, with EPS near $0.00.

Adastra Holdings Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.87 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -15.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 42.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.38 means current liabilities exceed short-term assets, a liquidity point worth watching.

Adastra Holdings Ltd. (XTXXF) Valuation Context

Relative to its peer group, XTXXF's quantitative score of 45/100 is below the peer average of 62/100.

Company Profile

Adastra Holdings Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Langley, CA. The company is led by CEO Brian O'Neill. XTXXF has traded publicly since 2021.

XTXXF Financials

XTXXF Latest News

No recent news available for XTXXF.

XTXXF Analyst Consensus

XTXXF MoonshotScore

XTXXF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources